Amyris ( Amyris )


Amyris's picture

Amyris delivers high-performance alternatives to petroleum-based products across a wide range of consumer and industry segments. Our products offer customers a way to reduce environmental impact with No Compromise® in performance or availability.

We developed innovative microbial engineering and screening technologies that modify the way microorganisms process sugars. Amyris is using its proprietary synthetic biology platform to design microbes, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into renewable hydrocarbons.

Our story began nearly a decade ago, when Amyris was founded with a vision of making a positive impact on the world through science. We first used our proprietary process to convert plant-sugars into an alternative, lower cost, stable supply of anti-malarial therapeutics. Thanks to our breakthrough technology, these life saving drugs are more readily accessible.

Today, our business strategy is focused on the production on Biofene®, Amyris’s brand of renewable farnesene, a long-chain branched hydrocarbon molecule, manufactured using Amyris-engineered microbes in fermentation of plant sugar feedstock.

Using Biofene as a first commercial building block molecule, we are developing a wide range of renewable specialty chemicals and fuels products, such as diesel and jet fuels, lubricants, polymers and plastic additives, flavors and fragrances, home and personal care, and cosmetics ingredients.

Amyris press release, blog etc

12/29/2017 - 06:38 DSM and Amyris Close Transactions for Brazilian Production Facility
11/17/2017 - 06:36 DSM Expands Strategic Alliance with Amyris and Acquires Brazilian Production Facility from Amyris
10/26/2017 - 05:32 H&R Makes Equity Investment in Novvi and its High-Performance Renewable Base Oil Technology
10/09/2017 - 10:23 Amyris Appoints Chief Operating Officer to Support Continued Strong Growth
10/05/2017 - 05:54 Amyris Enters into Product Development and Production Agreement with Royal DSM for Human Nutrition Ingredient
09/26/2017 - 07:43 Amyris Enters into Second Major Product Development and Production Agreement with Royal DSM
09/06/2017 - 04:12 Amyris to Present at Rodman & Renshaw 19th Annual Global Investment Conference on September 11, 2017
08/09/2017 - 04:18 Amyris Announces Closing of $50 Million in Second Tranche Equity Financing Fully Capitalized with Very Strong Business Momentum
08/03/2017 - 04:36 Amyris Announces Agreements For $50 Million in Second Tranche of Equity Financing, Exceeding Previous Target of $95 Million
07/26/2017 - 04:50 Amyris Biossance Launches in SEPHORA Canada Stores
07/17/2017 - 04:50 Amyris Enters Into First Product Development and Production Agreement With Royal DSM For Food and Nutrition Molecule
06/20/2017 - 12:26 Amyris Partners with Queensland on Biofutures Acceleration Program in Next Step Toward Planned Development of Biorefinery
06/06/2017 - 13:44 Amyris Announces Reverse Stock Split - Delivering on Strong Product Revenue Growth and Execution
05/22/2017 - 11:00 Amyris Exceeds Previous Debt Reduction Goal of $75 Million $86 Million In Debt Retired
05/15/2017 - 11:13 Amyris Reports 164% Product Revenue Growth over Prior Year & Continued Strong Outlook
05/11/2017 - 12:50 Royal DSM To Make Equity Investment In Amyris With the Purpose of Establishing a Long-Term Relationship
05/11/2017 - 12:08 Amyris Announces Closing Of First Tranche Of Up To $95 Million In Equity Financing And Conversion Of Over $55 Million Of Debt To Equity
05/10/2017 - 12:33 Amyris On-Track To Double Revenue For Vitamin E Partnership With Nenter & Announces Exclusive Vitamin A License With Royal DSM